225Ac-DOTATATE
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for 225Ac-DOTATATE, covering 2025-01-31 to 2025-01-31. Get the full timeline:
Most recent: Clinical Trial Update: A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors [Phase 1]